Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function

Sürder, Daniel; Manka, Robert; Lo Cicero, Viviana; Moccetti, Tiziano; Rufibach, Kaspar; Soncin, Sabrina; Turchetto, Lucia; Radrizzani, Marina; Astori, Giuseppe; Schwitter, Juerg; Erne, Paul; Zuber, Michel; Auf der Maur, Christoph; Jamshidi, Peiman; Gaemperli, Oliver; Windecker, Stephan; Moschovitis, Aris; Wahl, Andreas; Bühler, Ines; Wyss, Christophe; ... (2013). Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation, 127(19), pp. 1968-1979. Lippincott Williams & Wilkins 10.1161/CIRCULATIONAHA.112.001035

Preview

Text 1968.full.pdf - Published Version Available under License Publisher holds Copyright. Download (897kB) | Preview

BACKGROUND

Intracoronary administration of autologous bone marrow-derived mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute myocardial infarction. The optimal time point of administration of BM-MNC is still uncertain and has rarely been addressed prospectively in randomized clinical trials.

METHODS AND RESULTS

In a multicenter study, we randomized 200 patients with large, successfully reperfused ST-segment elevation myocardial infarction in a 1:1:1 pattern into an open-labeled control and 2 BM-MNC treatment groups. In the BM-MNC groups, cells were administered either early (i.e., 5 to 7 days) or late (i.e., 3 to 4 weeks) after acute myocardial infarction. Cardiac magnetic resonance imaging was performed at baseline and after 4 months. The primary end point was the change from baseline to 4 months in global LV ejection fraction between the 2 treatment groups and the control group. The absolute change in LV ejection fraction from baseline to 4 months was -0.4±8.8% (mean±SD; P=0.74 versus baseline) in the control group, 1.8±8.4% (P=0.12 versus baseline) in the early group, and 0.8±7.6% (P=0.45 versus baseline) in the late group. The treatment effect of BM-MNC as estimated by ANCOVA was 1.25 (95% confidence interval, -1.83 to 4.32; P=0.42) for the early therapy group and 0.55 (95% confidence interval, -2.61 to 3.71; P=0.73) for the late therapy group.

CONCLUSIONS

Among patients with ST-segment elevation myocardial infarction and LV dysfunction after successful reperfusion, intracoronary infusion of BM-MNC at either 5 to 7 days or 3 to 4 weeks after acute myocardial infarction did not improve LV function at 4-month follow-up.

Interest & Impact

Downloads

1537 since deposited on 19 Mar 2014
131 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item